Publications by authors named "J M Boher"
Article Synopsis
- Elderly AML patients (60-75 years) with poor-risk cytogenetics typically have poor outcomes with intensive chemotherapy, but the effectiveness of Venetoclax (VEN) combined with other treatments is being studied.
- A study at Institut Paoli Calmettes involved comparing 26 patients treated with VEN to a historical cohort of 90 patients treated with intensive chemotherapy, focusing on treatment response and overall survival rates.
- The findings suggested that VEN showed promising results, with a 69% composite response rate and a median overall survival of 7.9 months, making it a potential alternative to intensive chemotherapy for high-risk elderly patients.
Article Synopsis
- The LSC-17 score, based on a gene expression profile related to stemness, indicates poor outcomes in acute myeloid leukemia (AML), but how leukemic stem cell anchoring affects disease progression is unclear.
- Conditional inactivation of the adhesion molecule JAM-C in a mouse model of AML showed that its deletion affected HSC expansion but not disease initiation or progression, revealing insights into leukemic cell behavior in the bone marrow niche.
- Findings suggest that the AP-1/TNF-α gene signature, which correlated with different prognosis in AML, provides additional prognostic information alongside the LSC-17 score, highlighting the importance of niche interactions in leukemia.
Background: Current guidelines recommend using antifungals for selected patients with health care-associated intra-abdominal infection (HC-IAI), but this recommendation is based on a weak evidence. This study aimed to assess the association between early empirical use of antifungals and outcomes in intensive care unit (ICU) adult patients requiring re-intervention after abdominal surgery.
Methods: A retrospective, multicentre cohort study with overlap propensity score weighting was conducted in three ICUs located in three medical institutions in France.
Despite the widespread use of Cox regression for modeling treatment effects in clinical trials, in immunotherapy oncology trials and other settings therapeutic benefits are not immediately realized thereby violating the proportional hazards assumption. Weighted logrank tests and the so-called Maxcombo test involving the combination of multiple logrank test statistics have been advocated to increase power for detecting effects in these and other settings where hazards are nonproportional. We describe a testing framework based on supremum logrank statistics created by successively analyzing and excluding early events, or obtained using a moving time window.
View Article and Find Full Text PDFObjectives: Acute myeloid leukaemia (AML) and high-risk myelodysplastic syndromes (MDS) are often treated with intensive chemotherapy followed by allogeneic haematopoietic stem cell transplantation (allo-HSCT). The pretransplant treatment results in a general deterioration of the patient's health and quality of life. Furthermore, allo-HSCT can be responsible for significant toxicity with risks of graft-versus-host disease (GvHD).
View Article and Find Full Text PDF